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IMPACT OF RADIOGRAPHIC MAGNIFICATION CORREC- 
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POWER IN A CLINICAL TRIAL OF OSTEOARTHRITIS 
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Variability in magnification during radiography can affect the 
accuracy and precision of minimum joint space width (min-JSW) 
measurements in the knee. The aim of this study was to examine 
the effect of magnification correction on patient inclusion and 
sample size estimates based on mm-JSW in a multicenter clini- 
cal trial of osteoarthritis (OA). 
Methods: Bilateral knee radiographs of 490 OA patients (63 yrs ± 
8 yrs) were acquired at 47 centers in the US. Each knee was 
imaged on a separate film using posterior-anterior, weight-bear- 
ing, fixed-flexion on-fluoroscopic radiography with 10 ° beam 
angulation using a specially designed positioning frame. The 
frame was equipped with a reference phantom to allow verifica- 
tion of beam angulation and radiographic magnification using an 
integrated image analysis software. Radiographs were digitized 
to 100 mm, and min-JSW in the medial femorotibial joints meas- 
ured using a validated computerized edge detection algorithm 
shown to have a technical precision error (standard deviation 
[SD]) of 0.2 mm (duplicate imaging). 
Results: Radiographic magnification ranged from 2 % to 22 % 
(mean 9 %). Of the original 980 knees, 417 knees (269 patients) 
met eligibility criteria of ~2 mm and ~ 4mm min-JSW without 
magnification correction. After correction, 7 of these knees (7 
patients) showed min-JSW <2 mm, and 96 additional knees (83 
patients) showed min-JSW ft 4mm. Accordingly, magnification 
correction increased by 28% (76) the number of patients that met 
the eligibility criteria. Of these, 45 knees (45 patients) had follow- 
up radiography after one year. In this treated population the rate 
of joint-space narrowing (JSN) was 0.06 mm/year (SD = 0.42) 
without magnification correction a d 0.05 mm/year (SD = 0.38) 
with magnification correction. Magnification correction thus 
improved the SD of JSN by 12%. Such an improvement in preci- 
sion would allow a reduction in sample size of 18% for a 2-year 
clinical trial of OA (power = 80%, alpha = 0.05, 30% reduction in 
rate of JSN). 
Conclusions: These results show that radiographic magnification 
correction can substantially improve patient enrolment as well as 
statistical power in clinical trials of OA. 
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This study explored the relationship of hypercoagulability o the 
pathogenesis of osteoarthritis of the hip. Hypertrophy of the sub- 
chondral bone has been related to microcirculatory and venular 
thrombosis. Venous obstruction has been shown to result in 
increased bone production, stiffening, and decreased compliance 
of the subchondral bone plate. 
Methods: This is a cross-sectional study of the prevalence of 
hyper-coagulability in patients with osteoarthritis of the hip com- 
pared to an age- and gender-matched cohort without hip dis- 
ease. In all cases, osteoarthritis was confirmed by histopatholog- 
ical examination of the femoral head at total hip replacement. 
Sample size estimates with an c~ of 0.5 and a 13 of 0.20 suggest- 
ed that 35 patients per group would be adequate to detect a 25% 
difference in the incidence of any single coagulation test abnor- 
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mality. Fasting blood samples were drawn between 7 and 9 a.m. 
to minimize pre-analytical variables. Proteins C and S antigens 
were determined by ELISA. Resistance to activated protein C was 
measured functionally with a coagulometer. Factor VLeiden was 
assessed by PCR. Lipoprotein A was measured by enzyme 
immunoprecipitation assay with sequential mono- 
clonai/polyclonal sandwich technique. Plasminogen activator 
inhibitor was measured with synthetic substrates using a chro- 
mogenic assay. Tissue ptasminogen activator was measured in 
the antigenic form by ELISA and the functional form with a chro- 
mogenic assay. Anticardiolipin and lupus anticoagulant were 
measured by ELISA. 
Results: Evidence of hypofibrinolysis was present in 11% of 
patients with osteoarthritis of the hip (p=0.01). Elevations in 
antiphospholipid antibodies were notable. Eight patients had ele- 
vations in lupus anti-coagulant. Twelve patients had elevations in 
one or more anticardiolipin antibodies, either IgG or IgM. 
Seventeen patients (43%) had elevations in one or more 
antiphospholipid antibody (p<O.O001). 
Conclusions: The pathophysiology of microvascular obstruction 
and hypertrophy of the subchondral bone in osteoarthritis has 
been unclear. These studies suggest that a thrombotic tendency 
is present in a subset of patients with osteoarthritis compared to 
a similar population without hip disease, manifested primarily by 
elevations in antiphospholipid antibodies. These data provide an 
hypothesis for the formation of microcirculatory thrombosis and 
suggest that subchondral bone pathology in osteoarthritis in 
some patients may be related to an endotheliopathy. 
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Objective: To assess the effect of social companionship on 
health-related quality of life (HRQoL) in hip and knee osteoarthri- 
tis (QA). Design and setting: Prospective survey completed by hip 
and knee OA patients attending an outpatient physical rehabilita- 
tion clinic. 
Methods: HRQoL was assessed through the Medical 
Outcome Study Short Form 36 (SF-36). Social companionship 
evaluation was derived from the Social Support Questionnaire for 
Transactions and Satisfaction (Doeglas D et al 1996), which 
measures the number of supportive interaction (Social 
Companionship Transaction: SCT) as well as the satisfaction with 
the support perceived (Social Companionship Satisfaction: SCS). 
Regression analysis was used to assess the effect of SCT and 
SCS on each dimension of the SF-36. We controlled for age, sex, 
body mass index, number of comorbid conditions, socioeco- 
nomic status and severity of OA which was gauged with the pain 
dimension of the Western Ontario and McMaster Universities 
Osteoarthritis Index. 
Results: 107 patients agreed to complete the survey. SCT was 
found to have dramatic positive effects on mental health (b=2.41, 
p<0.001), physical functioning (13=1.98, p<0.001), social function- 
ing (1~=1.87, p=0.002), vitality (13=1.59, p=0.003), general health 
(133=1.55, p0.005) and, to a lesser extent, on role-emotional 
(13=0.16, p=0.035). SCS had a favorable impact on mental health 
(l~=1.86, p<0.001), social functioning (b=1.3t, p=0.023), physical 
functioning (13=0.98, p=0.043) and role-emotional (13=0.20, 
p=O.O07). 
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Conclusion: This study shows that both SCT and SCS have sub- 
stantial beneficial effects on HRQoL. By identifying patients 
socially isolated and by ensuring social integration of patients, 
future management of OA could lead to better health outcomes, 
especially in mental dimensions which have been consistently 
found to be impaired in OA. 
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~,im: The aim of this study was to assess the relationship 
between a recently published set of response criteria n knee OA 
and patients' global evaluation of efficacy. 
Methods: In knee OA patients (N=253) treated with Hylan G-F 20 
viscosupplementation, response rates according to patients' 
evaluation of efficacy (a "good" or "satisfactory" efficacy defin- 
ing "global responder" patients) were compared with OARSI 
response rates. OARSI knee intra-articular specific drug -propo- 
sition A and B- were studied (defining "OARSI A" or "OARSI B" 
responder patients). In these three populations of responders we 
described the absolute and relative mean changes over 9 months 
in WOMAC pain, WOMAC function and global assessment 
(patient's disease activity on a VAS). 
Results: OARSI A, OARSI B and global response rates were 
respectively 62.8%, 61.7% and 71.7%. Out of global responders, 
76.8% were OARSI A and 75.7% OARSI B responders. There 
were 87.5% and 87.9% global responders in OARSI A and B 
responders. 
Mean changes in the three responder populations were given 
below: 
OARSI A OARSI B Global 
responders 
Pain change 
- absolute (ram) - 35.6 + 14.8 
- relative (%) - 70.3 ± 20.6 
Function change 
- absolute (mm) -28.4 ± 15.7 
- relative (%) -62.7 ± 26.5 
Global assessment change 
- absolute (mm) - 41.7 + 21.4 
- relative (%) - 66.7 ± 30.0 
- 36.0 ± 14.7 - 29.6 ± 18.8 
- 70.6 ± 20.8 - 60.3 ± 32.3 
-29.0 ± 15.4 -23.3 ± 18.7 
-63.6 ± 25.4 -51.1 ± 40.6 
-41.9 ± 21.3 -35.6 ± 24.4 
- 67.0 ± 29.9 - 58.2 ± 39.5 
Conclusions: Higher mean changes in pain, function and global 
assessment are required to fulfill OARSI response criteria com- 
pared to patients' global response. Mean changes and response 
rates for knee intra-articular specific drug were similar whatever 
proposition A or B applied. 
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Bone marrow edema (BME) by magnetic resonance imaging 
(MRI) is a prominent finding of several pain syndromes. We 
hypothesized that subchondral BME coupled with information 
about the nature and location of focal cartilage defects would 
explain the conundrum of self-reported joint pain in the apparent 
absence of x-ray-defined knee osteoarthritis (OAK). A total of 
120 women grouped by self-reported pain and x-ray status (30 
per group) were identified from the Southeast Michigan Arthritis 
cohort of black-and white pre- and perimenopausal women 
(n=1053), aged 33-55, with weight bearing x-rays of both knees, 
self-reported knee joint pain and risk factors for OA. Definition of 
OAK was a Kellgren-Lawrence score of two or greater. 
Participants were evaluated using a 1.5 T (GE Sigma) scanner 
equipped with a knee surface coil. Sequences involved fast spin 
echo proton density with fat saturation sequences. Scoring for 
BME and cartilage defects were undertaken by two radiologists, 
blinded as to the x-ray OAK status and to group assignment. 
Group Pain x-ray OAK No BME No cartilage 
n=30/grp defect 
t No No 50% t7% 
2 No Yes 13% 0% 
3 Yes No 47% 20% 
4 Yes Yes 10% 0% 
Women with evidence of BME were 7 times more likely (95% 
C1=2.7,17.7) to be identified by x-ray as having OAK whereas the 
Odds ratio for BME and pain was 1.1 (95% Cl=0.5-2.5).The sum- 
mary BME in the worst knee did not account for self report of pain 
or account for the pain/x-ray OA incongruity in groups 2 and 3. 
BME is likely due to mild cellular injury, probably induced by 
micro-trauma. However, using a global measure of BME did not 
explain the dissonance between report of pain and x-ray findings. 
Further evaluation will be required to determine if comparison by 
compartment or severity is more explanatory of the dissonance. 
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Method: A cohort of patients with OA of the hand was evaluated 
in a planned subgroup analysis, using AUSCAN OA Hand Index 
in a trial assessing the gastrointestinal (GI) tolerability of rofecox- 
ib (RO) and naproxen (NA) in the treatment of patients with knee, 
hip, hand, or spine OA over 12 weeks. Eligible patients were ran- 
domly assigned to treatment with RO 25 mg qd or NA 500 mg 
bid. GI tolerability, as defined by the incidence of discontinuations 
due to GI adverse experiences (AE), was the primary endpoint. 
OA efficacy was assessed by the Patient Global Assessment of 
Disease Status (PGADS), the AUSCAN OA Hand Index LK3.0S, 
and discontinuations due to lack of efficacy (LOE). 
Results: 5557 patients received RO (n=2785) or NA (n=2772). 
Baseline characteristics were similar between treatment groups. 
16.4% of patients (n=447 and 463; RO and NA respectively) 
patients identified the hand as their primary source of OA symp- 
toms and were required to complete the AUSCAN questionnaire, 
a categorical scale (Pain/Difficulty: 1=None to 5=Extreme) to 
assess three domains of hand OA (pain, stiffness, and physical 
function, comprised of 5, 1 and 9 questions, respectively). 
Patients were asked to select one pain item and one physical 
function item which they most hoped would improve. Also, all 
patients completed the PGADS, a 100 mm VAS (0=very well; 
100=very poor). 
Rotecoxib Naproxen P value 
PGADS change (mm) Hand* - 6.94 - 6.41 N S 
AUSCAN Pain Domain" - 0.28 - 0.31 N S 
AUSCAN Stiffness Domain* - 0.39 - 0.33 N S 
AUSCAN Function Domain" - 0.37 - 0.38 N S 
Discontinuations due to LOF 6.4% 6.3% N S 
GIAEDiscontinuations 5.9% 8.1% 0 . 0 0 5 
"Reported as mean change from baseline 
